Grace Therapeutics (GRCE)
NASDAQ:GRCE
Want to see GRCE full AI Analyst Report?
Total Valuation
Grace Therapeutics has a market cap or net worth of $37.91M. The enterprise value is $21.10M.
Market Cap$37.91M
Enterprise Value$21.10M
Share Statistics
Grace Therapeutics has 15,474,026 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,474,026
Owned by Insiders8.48%
Owned by Institutions11.46%
Financial Efficiency
Grace Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -25.41%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.19
Return on Invested Capital (ROIC)-25.41%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-2.39M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Grace Therapeutics is ―. Grace Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio0.41
Price to Fair Value0.41
Price to FCF-1.85
Price to Operating Cash Flow-4.00
PEG Ratio0.05
Income Statement
In the last 12 months, Grace Therapeutics had revenue of 0.00 and earned -13.63M in profits. Earnings per share was -1.13.
Revenue0.00
Gross Profit0.00
Operating Income-23.75M
Pretax Income-18.18M
Net Income-13.63M
EBITDA-23.74M
Earnings Per Share (EPS)-1.13
Cash Flow
In the last 12 months, operating cash flow was -10.13M and capital expenditures 0.00, giving a free cash flow of -10.13M billion.
Operating Cash Flow-10.13M
Free Cash Flow-10.13M
Free Cash Flow per Share-0.65
Dividends & Yields
Grace Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-19.53%
50-Day Moving Average3.11
200-Day Moving Average3.35
Relative Strength Index (RSI)43.78
Average Volume (3m)58.56K
Important Dates
Grace Therapeutics upcoming earnings date is Jun 23, 2026, TBA (Confirmed).
Last Earnings DateFeb 12, 2026
Next Earnings DateJun 23, 2026
Ex-Dividend Date―
Financial Position
Grace Therapeutics as a current ratio of 11.77, with Debt / Equity ratio of 0.00%
Current Ratio11.77
Quick Ratio11.77
Debt to Market Cap0.00
Net Debt to EBITDA0.93
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Grace Therapeutics has paid -4.56M in taxes.
Income Tax-4.56M
Effective Tax Rate0.25
Enterprise Valuation
Grace Therapeutics EV to EBITDA ratio is -0.23, with an EV/FCF ratio of -0.36.
EV to Sales0.00
EV to EBITDA-0.23
EV to Free Cash Flow-0.36
EV to Operating Cash Flow-0.36
Balance Sheet
Grace Therapeutics has $18.67M in cash and marketable securities with $0.00 in debt, giving a net cash position of $18.67M billion.
Cash & Marketable Securities$18.67M
Total Debt$0.00
Net Cash$18.67M
Net Cash Per Share$1.21
Tangible Book Value Per Share$1.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Grace Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside30.43% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast70.83%